Non-Hodgkin lymphoma Posts Page 2 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

“Your Life Depends on Your Own Advocacy”

“Your Life Depends on Your Own Advocacy”

Posted by on Sep 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

“Always trust your gut. Don’t leave your treatment in the hands of someone that you don’t trust or that does not seem like a team player. Yes, they are all smart—even brilliant—but read, read, read, and question them at every corner and challenge the standard of care. Exercise, healthy eating, learning the ropes of insurance, mediation/prayer...

Read More

Evaluating the effectiveness of stem cell transplant in patients with follicular lymphoma with early treatment failure

Posted by on Sep 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...

Read More

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Posted by on Sep 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...

Read More

Evaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma

Posted by on Sep 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...

Read More

Evaluating the BR regimen in patients with low-tumor burden follicular lymphoma

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR regimen (rituximab, bendamustine) in elderly patients with untreated low-tumor burden follicular lymphoma (LTBFL). This study concluded that the BR regimen may provide positive outcomes for these patients. Some background Low-tumor burden follicular lymphoma (LTBFL) is a type of...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More

Evaluating the impact of omitting vincristine on the outcomes of patients with DLBCL

Posted by on Aug 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...

Read More

Evaluating the long-term risk of cardiovascular mortality in lymphoma survivors

Posted by on Aug 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term risk of cardiovascular mortality (death due to heart and blood vessel disease) among lymphoma survivors, compared to the general population. This study concluded that lymphoma survivors have a higher cardiovascular mortality risk compared to the general population.  Some background Advances in...

Read More

Clinical Trials Today

Clinical Trials Today

Posted by on Aug 26, 2018 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Nocturia, Non-Hodgkin lymphoma, Overactive bladder, Parkinson's Disease, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 4 comments

Prior to the 20th century, most people lived about 47 years in the developed world because of infectious diseases. In 1940, the first use of penicillin to treat infectious diseases occurred and penicillin became available in 1945 to the general public. Science and research conducted throughout the 1950s, 60s, and 70s, created more antibiotics so that life...

Read More